The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).

Original title: “Substances Generally Recognized as Safe”

The Health Center Program Scope of Project Policy Manual (Scope Manual) is program guidance to assist health centers in understanding what constitutes the Health Center Program scope of project under section 330 of the Public Health Service (PHS) Act.

Original title: “Notice of Availability of Final Health Center Program Scope of Project Policy Manual Guidance”

In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide an opportunity for public comment on proposed data collection projects, the National Institutes of Health, National Cancer Institute (NCI) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.

Original title: “Proposed Collection; 60-Day Comment Request Generic Clearance for the Collection of Customer Participation and Performance Management With NIH Programs, Products, and Services (Office of the Director)”

Referred to the House Committee on Ways and Means.

Original title: “HR 10072: To amend the Internal Revenue Code of 1986 to allow individuals entitled to Medicare Part A to make contributions to health savings accounts.”

The Food and Drug Administration (FDA) is proposing to reclassify digital breast tomosynthesis (DBT) systems, product code OTE, which are postamendments class III devices, from class III (premarket approval) into class II (special controls), subject to premarket notification. FDA is also proposing a new device classification regulation with the name "Digital Breast Tomosynthesis System," to identify these devices along with special controls that FDA believes are necessary to provide a reasonable

Original title: “Radiology Devices; Reclassification of Digital Breast Tomosynthesis System”

The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for DAYVIGO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.

Original title: “Determination of Regulatory Review Period for Purposes of Patent Extension; DAYVIGO”

The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BRINSUPRI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.

Original title: “Determination of Regulatory Review Period for Purposes of Patent Extension; BRINSUPRI”

The Food and Drug Administration (FDA, Agency, or we) has determined that OZOBAX (baclofen) oral solution, 5 milligrams (mg)/5 milliliters (mL), was not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to this drug product, and it will allow FDA to continue to approve ANDAs that refer to the product as long as they meet relevant legal and regulatory

Original title: “Determination That OZOBAX (Baclofen) Oral Solution, 5 Milligrams/5 Milliliters Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness”

Original title: “Office of the Director, Notice of Charter Renewal”

Referred to the Committee on Health, Education, Labor, and Pensions. (text: CR S4570-4571)

Original title: “SRES 848: A resolution celebrating the 80th anniversary of the Centers for Disease Control and Prevention, the premier public health institute of the United States.”

Referred to the House Committee on Energy and Commerce.

Original title: “HRES 1475: Expressing support for the designation of the first week of August as "National Community Health Center Week", and encouraging all Americans to participate by visiting their local community health center and celebrating the important partnership between health centers and the communities they serve.”

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Original title: “S 5193: Expanding Capacity for Health Outcomes Act of 2026”

The Centers for Disease Control and Prevention (CDC), located within the Department of Health and Human Services (HHS), announces five separate awards to fund Institute of Epidemiology, Disease Control and Research, Bangladesh; National Institute of Public Health, Cambodia; Institut Pasteur de Madagascar; National Health Laboratory Service, South Africa; L.Sakvarelidze National Center for Disease Control and Public Health, Georgia. For Institute of Epidemiology, Disease Control and Research, Ban

Original title: “Notice of Award of a Single Source Cooperative Agreement To Fund Institute of Epidemiology, Disease Control and Research, Bangladesh; National Institute of Public Health, Cambodia; Institut Pasteur de Madagascar; National Health Laboratory Service, South Africa; L.Sakvarelidze National Center for Disease Control and Public Health, Georgia.”

This NPRM proposes to rescind and replace the Head Start Program Performance Standards (Performance Standards), last revised in 2024. The proposed Performance Standards would significantly reduce Federal bureaucratic burden on programs; defer to State policies wherever possible; return substantial local control to Head Start agencies delivering the services and to parents as the primary caregivers and decision-makers for their children; reduce unnecessary duplication of Head Start regulations wi

Original title: “Reducing Federal Burden for Head Start Programs”

The Family and Youth Services Bureau's (FYSB) Runaway and Homeless Youth Division has a legislative requirement to fund a National Communication System, which is currently operated by the National Runaway Safeline (NRS). The NRS provides information, referral services, crisis intervention, and prevention resources to vulnerable youth at risk of running away and/or becoming homeless and their families or legal guardians at no cost. When necessary, the NRS refers runaway and homeless youth to shel

Original title: “Submission for Office of Management and Budget Review; National Communication System for Runaway and Homeless Youth, Currently Operated by the National Runaway Safeline Data Collection”

Submitted in the Senate, considered, and agreed to without amendment and with a preamble by Unanimous Consent. (consideration: CR S4553; text: CR S4568-4569)

Original title: “SRES 843: A resolution expressing support for the designation of the first week of August 2026, as "National Community Health Center Week", encouraging all people of the United States to participate by visiting their local community health center, and celebrating the important partnership between community health centers and the communities they serve.”

The Department of Health and Human Services (HHS) is delaying the effective date of the new routine use under the modified system of records maintained by the Office of Family Assistance (OFA) within HHS' Administration for Children and Families (ACF), System No. 09-80-0375, Temporary Assistance for Needy Families (TANF) Data that appeared in the Federal Register of June 23, 2026.

Original title: “Privacy Act of 1974; System of Records”

In compliance with the Paperwork Reduction Act of 1995, the National Institutes of Health (NIH) has submitted to the Office of Management and Budget (0MB) a request for review and approval of the information collection listed below.

Original title: “Submission for 0MB Review; 30-Day Comment Request”